Remove Immune Response Remove Presentation Remove Trials
article thumbnail

Designing antibodies to think before they bind

Drug Target Review

Engineering against resistance: the case of AP402 HER2-positive breast cancer already presents a therapeutic challenge, marked by aggressive tumour growth driven by overexpression of the HER2 receptor. The outcome is a bispecific designed to overcome resistance and activate the immune system precisely where it is needed.

article thumbnail

Outsmarting immune suppression through GPCR innovation

Drug Target Review

These CCR8+ Tregs are known to suppress immune responses in the tumour microenvironment (TME), allowing cancers to grow unchecked. “DT-7012 This knowledge will guide the strategic design and derisk its transition into Phase I/II trials to maximise success.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions.

article thumbnail

The Long Road to End Tuberculosis

Codon

Fortunately, some novel preventatives and therapies are in the works, including a vaccine equipped with adjuvants that efficiently prime the immune system and newer antibiotics against which the bacteria have yet to evolve resistance. tuberculosis , the same immune cells cross-react with the pathogen. Subscribe to Asimov Press.

Vaccine 113
article thumbnail

Scientists discover network of cells and genes involved in Crohn’s disease complication

Broad Institute

Drugs targeting strictures have failed in clinical trials, suggesting the need for a deeper look. One group of cells, a subpopulation of fibroblasts deep in the intestine, expressed particularly high levels of collagen and were present in patients with strictures.

Disease 111
article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

For some people with leukemia, lymphoma or multiple myeloma, they can prompt powerful responses and even long-lasting remission. But their administration also comes with notable risks, including a hyperactive immune response known as CRS and neurological toxicity dubbed ICANS. You can unsubscribe at anytime. TechTarget, Inc.s

Therapies 178
article thumbnail

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.